Jade Biosciences, Inc. (JBIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Jade Biosciences, Inc. stock (JBIO) is currently trading at $13.95. Analyst consensus price target for JBIO is $21.50. WallStSmart rates JBIO as Sell.
- JBIO PE ratio analysis and historical PE chart
- JBIO PS ratio (Price-to-Sales) history and trend
- JBIO intrinsic value — DCF, Graham Number, EPV models
- JBIO stock price prediction 2025 2026 2027 2028 2029 2030
- JBIO fair value vs current price
- JBIO insider transactions and insider buying
- Is JBIO undervalued or overvalued?
- Jade Biosciences, Inc. financial analysis — revenue, earnings, cash flow
- JBIO Piotroski F-Score and Altman Z-Score
- JBIO analyst price target and Smart Rating
Jade Biosciences, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Jade Biosciences, Inc. (JBIO) · 3 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Significant fundamental concerns warrant caution or avoidance.
Jade Biosciences, Inc. (JBIO) Key Strengths (1)
101.85% of shares held by major funds and institutions
Supporting Valuation Data
Jade Biosciences, Inc. (JBIO) Areas to Watch (2)
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Jade Biosciences, Inc. (JBIO) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 3 metrics analyzed, 1 register as strengths (avg 10.0/10) while 2 fall into concern territory (avg 5.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Market Cap, Price/Book. Some valuation metrics including Price/Book (2.08) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Market Cap and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
JBIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:27:56 AM
About Jade Biosciences, Inc.(JBIO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company is headquartered in Waltham, Massachusetts.